Literature DB >> 19783214

Antituberculosis activity of the molecular libraries screening center network library.

Joseph A Maddry1, Subramaniam Ananthan, Robert C Goldman, Judith V Hobrath, Cecil D Kwong, Clinton Maddox, Lynn Rasmussen, Robert C Reynolds, John A Secrist, Melinda I Sosa, E Lucile White, Wei Zhang.   

Abstract

There is an urgent need for the discovery and development of new antitubercular agents that target novel biochemical pathways and treat drug-resistant forms of the disease. One approach to addressing this need is through high-throughput screening of drug-like small molecule libraries against the whole bacterium in order to identify a variety of new, active scaffolds that will stimulate additional biological research and drug discovery. Through the Molecular Libraries Screening Center Network, the NIAID Tuberculosis Antimicrobial Acquisition and Coordinating Facility tested a 215,110-compound library against Mycobacterium tuberculosis strain H37Rv. A medicinal chemistry survey of the results from the screening campaign is reported herein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783214      PMCID: PMC2792876          DOI: 10.1016/j.tube.2009.07.006

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  29 in total

1.  Synthesis and biological activity of novel antibacterial quinazolines.

Authors:  Preet M S Bedi; V Kumar; Mohinder P Mahajan
Journal:  Bioorg Med Chem Lett       Date:  2004-10-18       Impact factor: 2.823

2.  [Synthesis and tuberculostatic activity of reaction products 5-(2-,3- and 4-pyridil) -1,3,4-oxadiazol-2-thione with amines].

Authors:  D Pancechowsak-Ksepko; H Foks; M Janowiec; Z Zwolska-Kwiek
Journal:  Acta Pol Pharm       Date:  1993       Impact factor: 0.330

3.  Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-butyl-3-substituted quinazolin-4-(3H)-ones.

Authors:  Veerachamy Alagarsamy; Viswas Rajasolomon; Ramseshu Meena; Kona Venkat Ramseshu
Journal:  Biol Pharm Bull       Date:  2005-06       Impact factor: 2.233

4.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Authors:  Sanjeev Kumar; Daniel Jaller; Bhumika Patel; Judith M LaLonde; James B DuHadaway; William P Malachowski; George C Prendergast; Alexander J Muller
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446

5.  Anilinopyrimidines as novel antituberculosis agents.

Authors:  Jody Morgan; Rachada Haritakul; Paul A Keller
Journal:  Bioorg Med Chem Lett       Date:  2003-05-19       Impact factor: 2.823

6.  Antibacterial activity of some 3-(arylideneamino)-2-phenylquinazoline-4(3H)-ones: synthesis and preliminary QSAR studies.

Authors:  Ashis Kumar Nanda; Subarna Ganguli; Ranadhir Chakraborty
Journal:  Molecules       Date:  2007-10-30       Impact factor: 4.411

7.  Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness.

Authors:  Ted Cohen; Megan Murray
Journal:  Nat Med       Date:  2004-09-19       Impact factor: 53.440

8.  Identification of novel inhibitors of methionyl-tRNA synthetase (MetRS) by virtual screening.

Authors:  John Finn; Mark Stidham; Mark Hilgers; Kedar G C
Journal:  Bioorg Med Chem Lett       Date:  2008-06-13       Impact factor: 2.823

9.  3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.

Authors:  Ji Yang; Parviz Gharagozloo; Jiangchao Yao; Victor I Ilyin; Richard B Carter; Phong Nguyen; Silvia Robledo; Richard M Woodward; Derk J Hogenkamp
Journal:  J Med Chem       Date:  2004-03-11       Impact factor: 7.446

10.  Extensively drug-resistant Mycobacterium tuberculosis, India.

Authors:  Rajesh Mondal; Amita Jain
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

View more
  68 in total

1.  Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

Authors:  Sean Ekins; Nadia K Litterman; Christopher A Lipinski; Barry A Bunin
Journal:  Pharm Res       Date:  2015-08-27       Impact factor: 4.200

2.  Computational models for neglected diseases: gaps and opportunities.

Authors:  Elizabeth L Ponder; Joel S Freundlich; Malabika Sarker; Sean Ekins
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

3.  A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteria.

Authors:  Deborah Mai; Jennifer Jones; John W Rodgers; John L Hartman; Olaf Kutsch; Adrie J C Steyn
Journal:  Assay Drug Dev Technol       Date:  2011-01-31       Impact factor: 1.738

4.  6-Oxo and 6-thio purine analogs as antimycobacterial agents.

Authors:  Ashish K Pathak; Vibha Pathak; Lainne E Seitz; William J Suling; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2013-02-04       Impact factor: 3.641

Review 5.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

Review 6.  Adapting high-throughput screening methods and assays for biocontainment laboratories.

Authors:  Lynn Rasmussen; Bersabeh Tigabu; E Lucile White; Robert Bostwick; Nichole Tower; Alexander Bukreyev; Barry Rockx; James W LeDuc; James W Noah
Journal:  Assay Drug Dev Technol       Date:  2015 Jan-Feb       Impact factor: 1.738

7.  Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis.

Authors:  Ruben C Hartkoorn; Olga B Ryabova; Laurent R Chiarelli; Giovanna Riccardi; Vadim Makarov; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

8.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.

Authors:  Sean Ekins; Robert C Reynolds; Hiyun Kim; Mi-Sun Koo; Marilyn Ekonomidis; Meliza Talaue; Steve D Paget; Lisa K Woolhiser; Anne J Lenaerts; Barry A Bunin; Nancy Connell; Joel S Freundlich
Journal:  Chem Biol       Date:  2013-03-21

9.  The DNA relaxation activity and covalent complex accumulation of Mycobacterium tuberculosis topoisomerase I can be assayed in Escherichia coli: application for identification of potential FRET-dye labeling sites.

Authors:  Gagandeep Narula; Jennifer Becker; Bokun Cheng; Neil Dani; Maria V Abrenica; Yuk-Ching Tse-Dinh
Journal:  BMC Biochem       Date:  2010-09-30       Impact factor: 4.059

10.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.